MTOR and renal cell carcinoma: For patients with advanced-grade or with distant metastases, some studies have shown that targeted therapy with tyrosine kinase inhibitors, VEGF-targeted drugs, or mTOR-targeted drugs has shown positive therapeutic effects in patients with SDH-deficient RCC [65,66].